The Effect of Arginine as an Anti-Aggregation Excipient on Recombinant Human Growth Hormone by Pazhouhandeh, Mehrdad et al.
Mehrdad Pazhouhandeha, Faranak Salmannejadb, Nastaran Nafissi-Varcheha and Maryam Tabarzadc*
a Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
b Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.









• Aggregation is one of the main physical instabilities of proteins. 
• Protein aggregation may result in a compromise of safety and efficacy of biopharmaceutical products. 
• Arginine at the concentration of 320 mM reduced rhGH thermal/mechanical-induced aggregation.
• Arginine, in contrast to glycine, optimally decreased the formation of insoluble aggregates.
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ABSTRACT
Aggregation is one of the main physical instabilities of proteins, which might occur 
during all steps of the manufacturing and storage of products. The presence of protein 
aggregates may result in the reduction of activity, induce immunologic responses and 
failure of therapeutic efficiency. Therefore, using additives in drug formulations is one 
of the essential approaches to prevent protein aggregation. The main objective of this 
study was to evaluate the inhibitory influence of arginine or glycine as excipients on 
the aggregation behavior of recombinant human growth hormone (rhGH). Two types of 
mechanical and thermal stresses including freeze-thaw and vortex-agitation were applied 
to the 1 mg/mL protein solution in PBS buffer (25 mM, pH = 7) in the presence and 
absence of arginine and glycine. The influence of arginine or glycine at the concentration 
of 320 mM on reduction of rhGH thermal/mechanical-induced aggregation was evaluated 
using SE-HPLC and turbidity measurement.The results of this study revealed that the 
monomer concentration decreased linearly; and therefore, aggregate formation was 
intensified with the increase in the number of freeze-thaw cycles. Moreover, it was found 
that a significant amount of rhGH (> 80%) was rapidly adsorbed at the walls of the vessels 
or converted to insoluble aggregates. Arginine decreased the insoluble aggregate formed 
during the freeze-thaw cycling more effectively than glycine. In addition, following the 
vortex-agitation stress, arginine had the optimum preventive effect in aggregate formation 
in contrast to glycine, which increased the formation of insoluble aggregates. The findings 
revealed that arginine may be a potential additive in preserving rhGH against thermal/
mechanical-induced aggregation.
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Introduction Human growth hormone (hGH) is a single-chain 
polypeptide and one of the most vital hormones with 
a wide variety of physiological functions including 
cell proliferation and metabolism (Bidlingmaier and 
Strasburger 2010; Mulinacci et al.,2011; Kim et al.,2013). 
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Pituitary-derived GH was first used in 1950s and since 
1985, the recombinant form of human growth hormone 
(rhGH) has been administered to treat growth hormone 
deficiency, especially in children (Cazares-Delgadillo 
et al., 2011). Nowadays, pharmaceutical products of 
rhGH are one of the most economical drugs with a wide 
market. The global market for rhGH seems to rise in 
value from $1.26 billion in 2014 to reach approximately 
$1.88 billion by 2024 (Gohil, 2015). rhGH, as a 191 
amino acids polypeptide, can be affected by physical or 
chemical instability mechanisms. Instability conditions 
in manufacturing and storage process may cause 
degradation of products of protein with reduced biological 
activity or augmented detrimental toxicity. One of the 
byproducts of protein instability is the aggregate form. 
Aggregation of rhGH could elevate the immunogenicity 
of its pharmaceutical product (Moore and Leppert, 1980; 
Fradkin et al., 2009).   
Aggregation of therapeutic proteins may result in dimer 
or higher- order aggregates as a consequence of stresses in 
production or storage conditions such as thermal, agitation 
or chemical stresses including inappropriate pH, ionic 
strength, counter-ion composition and addition of some 
excipients such as certain antimicrobial preservatives 
(Maggio, 2010). Protein aggregation may result in a 
compromise of safety and efficacy of biopharmaceutical 
products (Den Engelsman et al., 2011).
Various analytical techniques have been developed 
to characterize the protein samples with aggregation 
probability such as static and dynamic light scattering, 
size exclusion chromatography, turbidity measurement 
with spectrophotometry, microscopic analysis, fluorescent 
spectrophotometry,  circular dichroism spectroscopy, 
polyacrylamide gel electrophoresis (PAGE) and analytical 
ultracentrifugation (Maggio, 2010; Den Engelsman et 
al., 2011). Protein aggregates are commonly classified 
according to their size, reversibility, secondary/tertiary 
structure, covalent modification and morphology. In this 
respect, large and irreversible aggregates with covalent 
modifications will result in adverse changes of active 
conformation with more probability than reversible 
forms, and therefore, can compromise protein activity. 
Aggregate formation might stimulate immune response to 
the therapeutic protein product or cause adverse effects 
(Fradkin et al., 2009; Narhi et al., 2012). L-Arginine is a 
chemical additive, which has been applied in the refolding 
process of various proteins with different physicochemical 
characteristics (Bajorunaite et al., 2007). L-Arginine can 
act as an aggregation suppressor in protein purification 
process (Arakawa et al., 2007).
In this study, the protective potential of arginine for 
rhGH stability against aggregation events was examined. 
Two types of accelerated stability studies of freeze-thaw 
cycling and agitation stress were applied to one of the 
marketed rhGH formulations from LG Life Company. 
Aggregate formation was measured by turbidity 
analysis and size exclusion high performance liquid 
chromatography (SE-HPLC). 
Materials and Methods 
Materials
 
Recombinant human growth hormone was provided from 
Eutropin® (LG Life, Korea). Arginine and glycine were 
supplied form Merck-chemicals (Germany). Vivaspin® 
Turbo 4 ultrafiltration membrane was purchased from 
Sartorius (Germany). All other chemicals were supplied 
form Merck-chemicals (Germany).  
Sample Preparation
First, the lyophilized powder of rhGH was reconstituted 
and then purified by ultrafiltration membrane, and a 2 mg/
mL stock solution of rhGH in 25 mM sodium phosphate 
buffer (pH =7) was prepared. To obtain a 1 mg/mL rhGH 
containing a certain excipient, the stock solution was then 
mixed with PBS or buffered solutions of whether 640 mM 
arginine or glycine in a 1:1 ratio.
Freeze-Thaw Stress
400 µL of sample or control solution containing 1 mg/
ml rhGH in PBS was transferred into a 4-mL glass vial 
and capped. Nine vials were entered into the freeze-thaw 
study. Each cycle of freeze-thaw included 20 min in 
ethanol bath at -85º C followed by 15 min in water bath 
at room temperature (23-27º C). Three vials in each step 
were analyzed after second, eighth and sixteenth cycles 
of freeze-thaw.  Three control vials were kept refrigerated 
during the study. Then vials containing rhGH plus 320 mM 
arginine or glycine underwent 16 cycles of freeze-thaw (3 
copies of each). All samples were analyzed for soluble and 
insoluble aggregates by turbidometery and Size Exclusion-
High Performance Liquid Chromatography (SE-HPLC). 
Agitation Stress
Vortexing stress was carried out in glass test tubes (9 cm 
in height, 1.5 cm in diameter) filled by 500 µL of sample 
on a MS3 vortex (IKA, Germany). The vortexing rate was 
adjusted on 3000 rpm and the duration of the test was 7, 
20, 60 and 120 seconds (3 copies) for different samples. 
Three vials were kept at 4 º C as controls. Then, vials 
containing 320 mM arginine were vortexed at 3000 rpm 
for 7 seconds. Analysis was performed using turbidimetry 
or SE-HPLC.
Turbidity Measurements
The protein samples containing 1 mg/ml rhGH in 
33
The anti-aggregation effect of arginine on rhGH
25 mM phosphate buffer pH 7 were analyzed for 
aggregate formation in the absence and presence of 
320 mM L-arginine monohydrochloride. Turbidity was 
measured by sample absorbance at 405 nm after each 
stress condition. A sample of 0.15 mL was run for each 
measurement using UV/visible nano-spectrophotometer 
of ScanDrop 250 (Analytik Jena AG, Germany). 
Size Exclusion-High Performance Liquid 
Chromatography (SE-HPLC)
Alteration in the profile of monomers, dimers and soluble 
aggregates were analyzed by a set of TSKgel G3000PWXL 
column and guard column (Tosoh Bioscience Co., Japan) 
using a LC-10AD VP liquid chromatograph (Shimadzu 
co., Japan) at room temperature. A mobile phase of 63 
mM PBS containing 3% propan-2-ol and a flow of 0.4 
mL/min were considered. Furthermore, 20 μL of sample 
centrifuged at 7500 rpm was injected into the system and 
tracked by a UV-detector at 214 nm.
Results and Discussion
Effect of Freeze-Thaw Cycling on rhGH Aggregation 
In Freze-Thaw (FT) study of rhGH samples, increase 
in the number of cycles resulted in a linear elevation 
(r2 = 0.9974) of absorbance at 405 nm as a marker of 
insoluble aggregates from 0.0231 (± 0.0062) in control 
samples to 1.1414 (± 0.0742) in 16-cyc samples (Fig. 1). 
No lag-phase was observed and the test showed repeatable 
results. The turbidity difference of 0, 2, 8 and 16 cycles 
were strongly significant (p<0.05). Chromatographic data 
revealed a steady linear significant reduction in monomer 
recovery percentage from 100.0 (± 1.2) to 83.1 (± 3.2) in 
16-cycle FT samples (Fig. 2). No noteworthy changes were 
observed in dimers, but the fraction of soluble aggregates 
to the total protein decreased four folds permanently on 
early cycles of FT (data not shown).
During freeze-thaw cycling, adsorption of rhGH 
monomers on glass-liquid, ice or salt crystals-liquid 
and other interfaces initiated aggregation procedure. 
Adsorption occurred steadily with a constant rate and 
introduction of sticky hydrophobic patches on rhGH 
surface and promoted self-assembly of monomers on 
the interfaces, resulting in formation of aggregates. 
Subsequently, aggregated proteins detached from the 
surface and returned to the liquid phase, making the 
solution turbid. Moreover, pH alterations during freezing 
might change the microenvironment of rhGH monomer 
(Philo and Arakawa 2009). In phosphate buffers, these 
changes occur toward acidic condition (Bhatnagar et al., 
2007). Since pI of rhGH is around 5 (Wilhelmsen et al., 
2010), freeze-thaw cycling may reduce repulsive forces 
and mediate protein aggregation.
Effect of Vortexing on rhGH Aggregation 
Vortexing rhGH solution at 3000 rpm caused a drastically 
rapid turbidity formation, particularly within the first 20 
seconds. After 7 and 120 seconds of vortexing, absorbance 
raised to 0.9778 and 1.4474, respectively (Fig. 1). SE-
HPLC results revealed a huge loss of monomers in initial 
seconds followed by a plateau phase. Seven seconds 
of vortexing resulted in 53.6% reduction in monomer 
Figure 1. The Relationship between the Increase in the Number of FT Cycles on the Turbidity of rhGH Solution (boxes with oblique shades) 
and the Relationship between Vortex Duration and Turbidity of rhGH Solution (black line). Turbidity was determined by measuring the solution 
absorbance at 405 nm (n = 3, mean ± SEM).
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recovery (Fig. 2). Dimeric content underwent 3.3 to 4.6-
fold increase from 7 to 120 seconds, and soluble aggregates 
experienced a decrease from 0.4% in the control sample 
primarily and then grew to 1.0% in 120-second samples.
Vortexing is associated with high interfacial shear 
stresses; however, other mechanisms are also involved 
in agitation-induced aggregation of proteins. Agitation 
is accompanied with cavitation, shock waves, highly 
turbulent flow conditions, extreme pressures and 
temperature in the liquid phase, which may result in the 
generation of hydroxyl and hydrogen radicals and thus 
leading to the formation of protein aggregates (Mahler 
et al., 2009). Our experiment revealed that aside from 
insoluble aggregate formation, a substantial amount of 
rhGH absorbed on glass surface during vortexing, which 
emphasized the role of shear stress on monomer loss.
Effect of Arginine and Glycine on rhGH Aggregate 
Formation during Freeze-Thaw Cycling 
Turbidity measurement at 405 nm revealed that both 
arginine and glycine were efficient in lowering the amount 
Figure 2. Percent of Recovered Monomers from rhGH Solution after 0, 2, 8, and 16 Cycles of FT (boxes with oblique shades) and Percent of 
Recovered Monomers after 0, 7, 20, 60, and 120 Seconds of Vortexing (black line). Monomer content were analyzed using SE-HPLC, and recovery 
fraction were calculated by dividing AUC of monomers in the stressed sample to AUC of monomers in the control sample (n = 3, mean ± SEM).
Figure 3. The Effect of Arginine and Glycine on Formation of Insoluble Aggregates in rhGH Solution during FT or Vortex Stress. Not Stressed 
Control Samples (black boxes), Stressed Amino Acid-free Samples (boxes with oblique shades), Samples Containing 320 mM Arginine (vertically 
shaded boxes) and Samples Containing 320 mM Glycine (spotted gray boxes) (n = 3, mean ± SEM).
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of insoluble aggregate formation. While glycine could 
decrease absorbance to 0.4898 (± 0.0792) compared to 
1.1414 (± 0.0742) in amino acid-free samples, arginine 
strongly inhibited insoluble aggregation by an absorbance 
of 0.0295 (± 0.0004), which was statistically similar to 
control samples kept refrigerated (Fig. 3). 
 Sample analysis by SE-HPLC confirmed the positive 
influence of arginine on monomer content of the rhGH 
solution where it saved 96.3% (± 0.9) of monomers versus 
83.1% (± 3.2) monomers recovered from amino acid-free 
samples (p = 0.005). On the opposite side, glycine showed 
poor effect in monomer salvage. Recovery of monomers 
in samples containing 320 mM glycine was almost 4% 
less than amino acid-free samples, which was statistically 
insignificant (p = 0.26) (Fig. 4).  
One proposed mechanism of protein stabilization 
by amino acids is preferential exclusion. Some solutes 
increase surface tension of water, which is unfavorable 
in protein-aqueous phase interface. In addition, repulsive 
forces between functional groups of the solute and 
the protein chain might push solute molecules away 
from protein surface. In this method, a hydrated shell 
encompasses the protein and isolates it in a compact 
conformation, forcing hydrophobic parts to be buried 
in the core of the protein and preventing protein from 
denaturation, unfolding or aggregation (Arakawa and 
Timasheff 1983, Arakawa and Timasheff 1985). However, 
arginine seems to share a unique mechanism of action 
beyond preferential exclusion. The side chain of arginine 
resembles guanidine hydrochloride –a known denaturing 
agent- which is able to interact with all amino acid residues 
of protein chain. Nevertheless, arginine represents higher 
volume of exclusion and surface tension, and therefore, 
it is unable to denature proteins and the sum of these 
opposite forces endows a special ability to arginine.
Effect of Arginine and Glycine on rhGH Aggregate 
Formation during Vortexing  
Arginine performance in vortexing stress was promising. 
While 3000 rpm vortexing for 7 seconds severely produced 
insoluble particles in rhGH solution, adding 320 mM 
arginine could completely suppress aggregation with an 
absorbance of 0.0344 (± 0.0027). Glycine, recording the 
absorbance of 1.1648 (± 0.0465) at 405 nm, conversely 
deteriorated particle formation, but insignificantly (p = 
0.051) (Fig. 3).
SE-HPLC data ascertained the positive role of arginine 
in rhGH stabilization against agitation stress. Addition of 
arginine to rhGH solution unexpectedly improved monomer 
recovery whereas glycine might have destabilized the 
protein monomers. Monomer recovery percentage for 
arginine, glycine and amino acid-free samples were 85/3% 
(± 2.1), 35/5% (± 2.8) and 46/4% (± 2.1), respectively (all 
differences were significant) (Fig. 4).
It is thermodynamically favorable that arginine binds 
to protein residues. Since proteins offer a larger surface 
in monomeric form rather than aggregated or adsorbed 
form, the equation shifts toward monomeric units which 
is accompanied by lower level of Gibbs free energy 
(Tsumoto et al., 2005; Arakawa et al., 2007). Overall, 
presence of arginine in rhGH solution protected this 
protein against aggregation as well as adsorption on the 
glass surface during both freeze-thaw test and high shear 
vortex-agitation.
On the other hand, protein destabilization by 
Figure 4. The Effect of Arginine and Glycine on the Percent of Recovery of Monomers in rhGH Solution during FT or Vortex Stress. Stressed 
Amino Acid-free Samples (boxes with oblique shades), Samples Containing 320 mM arginine (vertically shaded boxes) and Samples Containing 
320 mM Glycine (spotted gray boxes) (n = 3, mean ± SEM).
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osmolytes –like what was observed in glycine case- was 
reported in some experiments, but it is mechanistically 
unknown. However, we are aware that the preferential 
binding of the osmolyte with the protein that originates 
from a favorable interaction between the osmolyte and 
protein side chains, favors denatured state; and denaturing 
osmolytes accumulate or bind at the surface and promote 
unfolding (Singh et al., 2011).        
According to the results, arginine did not show a 
denaturing effect on rhGH, but it unexpectedly improved 
protein stability and monomer recovery. 
Conclusion
In this study, the effect of arginine and glycine on the 
aggregation of recombinant human growth hormone 
was examined during freeze-thaw and agitation stresses. 
Arginine, through its unique chemical structure, 
successfully overcame the harsh accelerated studies 
and stabilized rhGH to a great extent, whereas glycine 
–the typical amino acid based excipient- appeared to 
be destabilizing rather than stabilizing. According to 
the literature review, this was the first report on the 
positive effect of arginine (or any other amino acids) 
on the stabilization of proteins during agitation stress. 
Nevertheless, further studies are necessary to confirm this 
effect.  
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